Eli Lilly’s President of Oncology to retire

Just as it ramps up its cancer-fighting efforts, Eli Lilly has revealed that its Senior Vice President and President of Lilly Oncology Sue Mahony is set to retire from her role, effective 31 August.

Mahony’s time with the firm has lasted 18 years since she originally jumped on board in 2000, and during that time she has spearheaded a number of key projects, such as the integration of ImClone, and launched a range of Lilly products including cancer drug Verzenio. Prior to the announcement of her intention to leave the role, she was also instrumental in reengineering Lilly’s oncology R&D strategy.

Before her time with Lilly, Mahony had built up over a decade of sales and marketing experience within Europe at several major industry players including Bristol Myers-Squibb, Amgen and Schering-Plough.

David A Ricks, Lilly's chairman and Chief Executive Officer, commented: "On behalf of our executive team and the company, I want to thank Sue for her leadership over the past 18 years. Her passion for patients and strong sense of purpose are inspiring to all of us."

Mahony herself remarked: "What I've appreciated over the years is the opportunity to participate in something greater than myself. We make medicines that help patients with cancer live longer. What a privilege it's been to wake up each morning with that as my life's work."

Lilly confirmed it is currently looking both internally and externally for Mahony’s replacement.

Register as Visitor to CPhI China 2018!